


CLAIMS

We claim:

1. A compound having a structure according to formula I









5 and the pharmaceutically acceptable salts, esters, and prodrug forms thereof
wherein


R¹ is OMe or R²R³N, where R² and R³ are independently H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈
alkynyl, cycloalkyl, heterocyclo, aryl, or heteroaryl; or R² and R³ and the nitrogen to which
they are attached combine to form a substituted or unsubstituted 3, 4, 5, 6, or 7 membered
ring; and

10 R⁴ is H or CH₂C(=O)R⁵, where R⁵ is a substituted or unsubstituted phenyl group.


2. A compound according to claim 1, wherein R⁴ is H.
3. A compound according to claim 2, wherein R¹ is MeO.
4. A compound according to claim 2, wherein R¹ is R²R³N, where R² is H and R³ is a
15 substituted C₁-C₈ alkyl.
5. A compound according to claim 4, wherein R³ is a substituted C₂ alkyl group.

6. A compound according to claim 5, wherein the substituent is selected from the group consisting of fluoro, cycloalkylamino, dialkylamino, heterocyclo having at least one nitrogen ring atom, and heteroaryl having at least one nitrogen ring atom.
7. A compound according to claim 2, wherein R^1 is R^2R^3N , where R^2 is H and R^3 is allyl.
- 5 8. A compound according to claim 2, wherein R^1 is R^2R^3N , where R^2 and R^3 are each H.
9. A compound according to claim 2, wherein R^1 is R^2R^3N , where R^2 and R^3 and the nitrogen to which they are attached combine to form a substituted or unsubstituted 3, 4, 5, 6, or 7 membered ring.
10. A compound according to claim 2, wherein R^1 is selected from the group consisting of
- 10  ,  ,  ,  ,
 ,  ,  ,  ,
and  .
- 15 11. A compound according to claim 2, having a K_d for Hsp90 binding of 4 μM or less.
12. A compound according to claim 2, having an IC_{50} towards SKBr3 cells of 300 nM or less.
13. A compound according to claim 1, wherein R^4 is $\text{CH}_2\text{C}(=\text{O})\text{R}^5$.


14. A compound according to claim 1, having a structure according to formula I-b



15. A compound according to claim 1, having a structure according to formula I-i



5 16. A compound according to claim 1, having a structure according to formula I-j




17. A method of inhibiting the proliferation of a target cell, comprising contacting the target cell with an effective amount of a compound having a structure according to claim 1.


18. A method according to claim 17, wherein the target cell is a cancer cell.

19. A method according to claim 18, wherein the cancer cell is a breast cancer, lung cancer,
5 ovarian cancer, or leukemia cell.


20. A method according to claim 19, wherein the compound according to claim 1 has a structure according to formula I-b



21. A method according to claim 19, wherein the compound according to claim 1 has a
10 structure according to formula I-i



22. A method according to claim 19, wherein the compound according to claim 1 has a structure according to formula I-j




23. A method of treating a hyperproliferative disease, comprising administering to a patient suffering from such hyperproliferative disease a therapeutically effective amount of a compound according to claim 1.


24. A method according to claim 23, wherein the hyperproliferative disease is cancer.

25. A method according to claim 24, wherein the cancer is breast cancer, lung cancer, ovarian cancer, or leukemia.


26. A method according to claim 25, wherein the compound according to claim 1 has a structure according to formula I-b



27. A method according to claim 25, wherein the compound according to claim 1 has a structure according to formula I-i



28. A method according to claim 25, wherein the compound according to claim 1 has a
5 structure according to formula I-j




29. The use of a compound according to claim 1 for the preparation of a medicament for treating a hyperproliferative disease.


30. The use of claim 29, wherein the hyperproliferative disease is cancer.

10 31. The use of claim 30, wherein the cancer is breast cancer, lung cancer, ovarian cancer, or leukemia.

32. The use of claim 31, wherein the compound according to claim 1 has a structure according to formula I-b



33. The use of claim 31, wherein the compound according to claim 1 has a structure according
5 to formula I-i



34. The use of claim 31, wherein the compound according to claim 1 has a structure according to formula I-j

